BM-51

BM-51 potently inhibits the enzymatic activity of CYP4Z1 (IC₅₀ = 91.7 nM)^[1] by binding to the Arg384, Ser383, Val126 and Ala314 amino acid residues of CYP4Z1 in HEK293T cell lysates.
BM-51 (500 μM; 30 min) directly binds to the Arg384, Ser383, Val126 and Ala314 sites of CYP4Z1 in protein extracts^[1].
BM-51 reduces the mammosphere-forming capacity (a tumor-initiating cell-like trait) of 4T1 cells overexpressing wild-type CYP4Z1, but exerts no such effect on cells overexpressing CYP4Z1^Arg384, CYP4Z1^Ser383, CYP4Z1^Val126 or CYP4Z1^Ala314[1].
BM-51 reduces the proportion of CD44⁺/CD24⁻ tumor-initiating cell (TIC) subsets in 4T1 cells overexpressing wild-type CYP4Z1, but exerts no such effect on cells overexpressing CYP4Z1 with mutations at Arg384, Ser383, Val126 or Ala314^[1].
BM-51 (0.01-100 μM; 72 h) shows no significant inhibitory effect on cell viability in MCF-7, MDA-MB-231 and 4T1 cells^[1].
BM-51 (0.25-10 μM; 24-48 h) exhibits significant inhibitory effects on cell migration in MCF-7 and MDA-MB-231 cells ^[1].
BM-51 (0.25-10 μM) downregulates the protein expression levels of stem cell markers ALDH1A1, SOX2, OCT3/4 and KLF4 in MCF-7 and MDA-MB-231 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.